OTC
VYGR icon

Opera Trading Capital’s Voyager Therapeutics VYGR Stock Holding History

Opera Trading Capital’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,474
Closed -$47K – 163
2018
Q3 		$47K Buy
+2,474
New +$47.5K 0.01% 145

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Opera Trading Capital's VYGR Position: Q4 2018 in Review

Opera Trading Capital sold out of Voyager Therapeutics (VYGR) in Q4 2018, closing a stake of 2,474 shares — an estimated $47K sold.

Opera Trading Capital first reported a position in VYGR in Q3 2018 and held it in 1 quarter. The position peaked at $47K in Q3 2018. 116 funds tracked by Wall St. Rank hold VYGR as of Q4 2018.

  • Opera Trading Capital reported no remaining Voyager Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Opera Trading Capital sold 2,474 Voyager Therapeutics shares in Q4 2018, an estimated $47K.
  • Opera Trading Capital first reported a position in Voyager Therapeutics in Q3 2018 and held it in 1 quarter.
  • Opera Trading Capital's Voyager Therapeutics position peaked at $47K in Q3 2018.
  • 116 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2018.

Based on Opera Trading Capital's 13F filing for Q4 2018, filed 22 Jan 2019.